Introduction: Alzheimer’s disease has a 1. 6% of prevalence in people over 65 years of age. It is characterized by loss of memory and other cognitive functions, but more of the 70% of affected have non-cognitive symptoms as alterations of mood, behavior and psychosis. These symptoms are associated to increased rates of institutionalization, morbidity and mortality. Methods: Systematic review of literature from papers that provided information about efficacy of selective serotonin reuptake inhibitors in Alzheimer’s non-cognitive symptoms. Results: Initial search resulted in 495 papers, 64 articles were pre-selected and 7 were included in review, these were classified as level of evidence Ib, Citalopram showed to be more effective than placebo and similar to antipsychotics for behavioral and psychotic symptoms of Alzheimer’s disease with more tolerable profile of adverse effects; Sertraline didn’t show efficacy in depression but an increased incidence of adverse effects compared against placebo. Discussion: Favorable results were achieved in behavioral and psychotic symptoms but not in emotional symptoms. Methodological differences among the studies give complexity to interpretation of results. Conclusions: Evidence suggests that Citalopram’s treatment is effective in behavioral and psychotic symptoms associated to Alzheimer’s disease; for treatment of depression associated to this dementia does not yet exist an antidepressant that can consider treatment of choice.